SIRT6 and hepatocellular carcinoma: Previous studies showed that knockdown of SIRT6 can inhibit MAPK/ERK and PI3K/AKT/mTOR signaling pathways in hepatocellular carcinoma and diffuse large B-cell lymphoma [32, 33].